What this is
- How it works
- How it works isn't classified yet
- Tested for
- Stargardt Disease 1, STGD1
- Main trialPhase 1
- “This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.”In the company’s words, NCT07836452 on ClinicalTrials.gov
Other drugs for Stargardt Disease 1
Coming up1
- Feb 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Feb 2028 | A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026